Yuchao Yang

Adelaide, SA 5000, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation.

Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation.

Journal: Molecules (Basel, Switzerland)

Published: March 03, 2023

Discovery of Potent Inhibitors of Cyclin-Dependent Kinases 7 and 9: Design, Synthesis, Structure-Activity Relationship Analysis and Biological Evaluation.

Discovery of Potent Inhibitors of Cyclin-Dependent Kinases 7 and 9: Design, Synthesis, Structure-Activity Relationship Analysis and Biological Evaluation.

Journal: ChemMedChem

Published: October 31, 2022

An overview of CDK3 in cancer: clinical significance and pharmacological implications.

An overview of CDK3 in cancer: clinical significance and pharmacological implications.

Journal: Pharmacological research

Published: April 07, 2022

Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer.

Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer.

Journal: Journal of medicinal chemistry

Published: March 21, 2022

EWI2 prevents EGFR from clustering and endocytosis to reduce tumor cell movement and proliferation.

EWI2 prevents EGFR from clustering and endocytosis to reduce tumor cell movement and proliferation.

Journal: Cellular and molecular life sciences : CMLS

Published: February 18, 2022

Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.

Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.

Journal: European journal of medicinal chemistry

Published: February 16, 2021

Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.

Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.

Journal: European journal of medicinal chemistry

Published: December 21, 2020

Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2.

Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2.

Journal: Molecular pharmacology

Published: May 27, 2015

Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia.

Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia.

Journal: Molecular pharmacology

Published: January 19, 2015

Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.

Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.

Journal: Cancer letters

Published: October 15, 2014

An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.

An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.

Journal: European journal of medicinal chemistry

Published: September 11, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026